A Phase 2 Study of Pembrolizumab in Combination With Pelareorep in Patients With Advanced Pancreatic Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Pelareorep (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 06 Nov 2019 According to an Oncolytics Biotech media release, terim results from this trial are expected in the first half of 2020 and complete patient enrollment around mid-2020.
- 26 Nov 2018 According to an Oncolytics Biotech media release, the company today announced that the first patient has been treated in this study.
- 26 Nov 2018 Status changed from not yet recruiting to recruiting, according to an Oncolytics Biotech media release.